Publications by authors named "D D Clark"
Current approaches to the surgical management of Crohn's disease in Australia and New Zealand.
Int J Colorectal Dis
January 2025
Purpose: Given the evolving literature regarding the optimal surgical approach to mitigate post-operative recurrence of Crohn's disease (CD), this survey study aimed to elucidate the practices and preferences of colorectal surgeons in Australia and New Zealand (ANZ) in their surgical management of CD.
Methods: Colorectal surgical consultants and fellows (n = 337) registered with the Colorectal Surgical Society of Australia and New Zealand (CSSANZ) were invited by email in April 2022 to participate in a cross-sectional survey consisting of basic demographics and 12 questions relating to their usual surgical practice and preferred operative strategy.
Results: A total of 135 responses were received (39.
Article Synopsis
- High-dose testosterone replacement therapy (TRT) combined with finasteride offers benefits such as improved body composition, muscle strength, and bone density in older men, while mitigating the risk of prostate enlargement.
- A pilot study involved 12 men with spinal cord injuries, demonstrating that TRT with finasteride significantly increased lean body mass and muscle size, alongside enhancing bone mineral density compared to a placebo.
- Results suggest TRT + finasteride reduced fat mass and improved muscular strength, with measurable benefits observed as early as 6 months into the treatment, indicating its potential effectiveness for men with low testosterone post-injury.
Introduction: Psychotropic medication (PM) use in behavioral-variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD.
Methods: We analyzed data from sporadic and genetic bvFTD participants with PM prescriptions in the Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects study.
Introduction: Early-onset Alzheimer's disease (EOAD) manifests prior to the age of 65, and affects 4%-8% of patients with Alzheimer's disease (AD). The current analyses sought to examine longitudinal cognitive trajectories of participants with early-onset dementia.
Methods: Data from 307 cognitively normal (CN) volunteer participants and those with amyloid-positive EOAD or amyloid-negative cognitive impairment (EOnonAD) were compared.
Introduction: Early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD) share similar amyloid etiology, but evidence from smaller-scale studies suggests that they manifest differently clinically. Current analyses sought to contrast the cognitive profiles of EOAD and LOAD.
Methods: Z-score cognitive-domain composites for 311 amyloid-positive sporadic EOAD and 314 amyloid-positive LOAD participants were calculated from baseline data from age-appropriate control cohorts.